Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Isatuximab in combination with carfilzomib and dexamethasone in 1q21+ patients with relapsed/refractory multiple myeloma: Long-term outcomes in the Phase 3 IKEMA study

T. Facon, P. Moreau, I. Špicka, K. Suzuki, K. Yong, J. Mikhael, T. Fukao, K. Bisht, NM. Armstrong, S. Macé, ML. Risse, T. Martin

. 2024 ; 42 (2) : e3258. [pub] -

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc24006848

Grantová podpora
Sanofi

Gain/amplification of 1q21 (≥3 copies), a chromosomal abnormality frequently observed in multiple myeloma, can negatively affect prognosis, due to its involvement in resistance to anti-myeloma therapy and disease progression. In this updated subgroup analysis of the randomized, Phase 3 IKEMA study (NCT03275285) in relapsed/refractory multiple myeloma (RRMM), we evaluated progression-free survival (PFS) and depth of response with the anti-CD38 antibody isatuximab plus carfilzomib-dexamethasone (Isa-Kd) versus Kd, in 1q21+ patients and related subgroups, at long-term follow-up (44.2 months). Our analysis included patients with 1q21+ (≥3 copies, with/without high-risk chromosomal abnormality [HRCA]), isolated 1q21+ (≥3 copies, without HRCA), gain(1q21) (3 copies, with/without HRCA), and amp(1q21) (≥4 copies, with/without HRCA). PFS benefit was achieved with Isa-Kd versus Kd in patients with 1q21+ (HR 0.58, 95% CI: 0.37-0.92), with isolated 1q21+ (HR 0.49, 95% CI: 0.27-0.92), with gain(1q21), or amp(1q21), consistent with the overall population and prior interim 1q21+ subgroup analyses. Median PFS with Isa-Kd versus Kd was 25.8 versus 16.2 months in 1q21+ patients and 38.2 versus 16.2 months in patients with isolated 1q21+. Clinically meaningful, higher rates of very good partial response or better, complete response or better (≥CR), minimal residual disease (MRD) negativity, and MRD negativity and ≥CR were reached with Isa-Kd versus Kd in patients with 1q21+, isolated 1q21+, gain(1q21), or amp(1q21). In Isa-Kd and Kd, the MRD negativity and ≥CR rate was 29.3% versus 15.4% in 1q21+ patients, 36.2% versus 12.9% in patients with isolated 1q21+, 27.9% versus 13.5% in patients with gain(1q21), and 31.3% versus 20.0% in patients with amp(1q21), respectively. In conclusion, addition of Isa to Kd in triplet combination therapy has shown PFS benefit and deeper responses, compared with Kd, in 1q21+ patients at higher risk of progression, including patients with isolated 1q21+, gain(1q21), and amp(1q21), thus supporting Isa-Kd an effective treatment option for patients with RRMM.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24006848
003      
CZ-PrNML
005      
20240423155530.0
007      
ta
008      
240412s2024 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1002/hon.3258 $2 doi
035    __
$a (PubMed)38402467
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Facon, Thierry $u Department of Hematology, Lille University Hospital, Lille, France
245    10
$a Isatuximab in combination with carfilzomib and dexamethasone in 1q21+ patients with relapsed/refractory multiple myeloma: Long-term outcomes in the Phase 3 IKEMA study / $c T. Facon, P. Moreau, I. Špicka, K. Suzuki, K. Yong, J. Mikhael, T. Fukao, K. Bisht, NM. Armstrong, S. Macé, ML. Risse, T. Martin
520    9_
$a Gain/amplification of 1q21 (≥3 copies), a chromosomal abnormality frequently observed in multiple myeloma, can negatively affect prognosis, due to its involvement in resistance to anti-myeloma therapy and disease progression. In this updated subgroup analysis of the randomized, Phase 3 IKEMA study (NCT03275285) in relapsed/refractory multiple myeloma (RRMM), we evaluated progression-free survival (PFS) and depth of response with the anti-CD38 antibody isatuximab plus carfilzomib-dexamethasone (Isa-Kd) versus Kd, in 1q21+ patients and related subgroups, at long-term follow-up (44.2 months). Our analysis included patients with 1q21+ (≥3 copies, with/without high-risk chromosomal abnormality [HRCA]), isolated 1q21+ (≥3 copies, without HRCA), gain(1q21) (3 copies, with/without HRCA), and amp(1q21) (≥4 copies, with/without HRCA). PFS benefit was achieved with Isa-Kd versus Kd in patients with 1q21+ (HR 0.58, 95% CI: 0.37-0.92), with isolated 1q21+ (HR 0.49, 95% CI: 0.27-0.92), with gain(1q21), or amp(1q21), consistent with the overall population and prior interim 1q21+ subgroup analyses. Median PFS with Isa-Kd versus Kd was 25.8 versus 16.2 months in 1q21+ patients and 38.2 versus 16.2 months in patients with isolated 1q21+. Clinically meaningful, higher rates of very good partial response or better, complete response or better (≥CR), minimal residual disease (MRD) negativity, and MRD negativity and ≥CR were reached with Isa-Kd versus Kd in patients with 1q21+, isolated 1q21+, gain(1q21), or amp(1q21). In Isa-Kd and Kd, the MRD negativity and ≥CR rate was 29.3% versus 15.4% in 1q21+ patients, 36.2% versus 12.9% in patients with isolated 1q21+, 27.9% versus 13.5% in patients with gain(1q21), and 31.3% versus 20.0% in patients with amp(1q21), respectively. In conclusion, addition of Isa to Kd in triplet combination therapy has shown PFS benefit and deeper responses, compared with Kd, in 1q21+ patients at higher risk of progression, including patients with isolated 1q21+, gain(1q21), and amp(1q21), thus supporting Isa-Kd an effective treatment option for patients with RRMM.
650    _2
$a lidé $7 D006801
650    12
$a mnohočetný myelom $7 D009101
650    _2
$a dexamethason $x terapeutické užití $7 D003907
650    _2
$a chromozomální aberace $7 D002869
650    _2
$a protokoly protinádorové kombinované chemoterapie $x terapeutické užití $7 D000971
650    12
$a oligopeptidy $7 D009842
650    12
$a humanizované monoklonální protilátky $7 D061067
655    _2
$a časopisecké články $7 D016428
700    1_
$a Moreau, Philippe $u Department of Hematology, University Hospital Hôtel-Dieu, Nantes, France
700    1_
$a Špicka, Ivan $u Department of Hematology, 1st Faculty of Medicine, Charles University and General Hospital, Prague, Czech Republic
700    1_
$a Suzuki, Kenshi $u Myeloma/Amyloidosis Center, Japanese Red Cross Medical Center, Tokyo, Japan
700    1_
$a Yong, Kwee $u Department of Haematology, University College Hospital, London, UK
700    1_
$a Mikhael, Joseph $u Translational Genomics Research Institute, City of Hope Cancer Center, Phoenix, Arizona, USA
700    1_
$a Fukao, Taro $u Sanofi, Global Oncology, Cambridge, Massachusetts, USA
700    1_
$a Bisht, Kamlesh $u Sanofi, Global Oncology, Cambridge, Massachusetts, USA
700    1_
$a Armstrong, Nicole M $u Sanofi, Global Medical Affairs, Cambridge, Massachusetts, USA
700    1_
$a Macé, Sandrine $u Sanofi, Research and Development, Chilly-Mazarin, France
700    1_
$a Risse, Marie-Laure $u Sanofi, Research and Development, Vitry-Sur-Seine, France
700    1_
$a Martin, Thomas $u University of California San Francisco Medical Center, San Francisco, California, USA
773    0_
$w MED00002019 $t Hematological oncology $x 1099-1069 $g Roč. 42, č. 2 (2024), s. e3258
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38402467 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240412 $b ABA008
991    __
$a 20240423155527 $b ABA008
999    __
$a ok $b bmc $g 2081054 $s 1216615
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 42 $c 2 $d e3258 $e - $i 1099-1069 $m Hematological oncology $n Hematol Oncol $x MED00002019
GRA    __
$p Sanofi
LZP    __
$a Pubmed-20240412

Najít záznam

Citační ukazatele

Možnosti archivace